Prenatal intravenous magnesium at 30-34 weeks' gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial
CA Crowther, P Ashwood, PF Middleton, A McPhee… - Jama, 2023 - jamanetwork.com
Importance Intravenous magnesium sulfate administered to pregnant individuals before birth
at less than 30 weeks' gestation reduces the risk of death and cerebral palsy in their …
at less than 30 weeks' gestation reduces the risk of death and cerebral palsy in their …
[PDF][PDF] Prenatal Intravenous Magnesium at 30-34 Weeks' Gestation and Neurodevelopmental Outcomes in Offspring The MAGENTA Randomized Clinical Trial
CA Crowther, P Ashwood, PF Middleton, A McPhee - JAMA, 2023 - researchgate.net
Prenatal Intravenous Magnesium at 30-34 Weeks’ Gestation and Neurodevelopmental
Outcomes in Offspring: The MAGENTA Randomized Page 1 Prenatal Intravenous Magnesium at …
Outcomes in Offspring: The MAGENTA Randomized Page 1 Prenatal Intravenous Magnesium at …
Prenatal Intravenous Magnesium at 30-34 Weeks' Gestation and Neurodevelopmental Outcomes in Offspring: The MAGENTA Randomized Clinical Trial.
CA Crowther, P Ashwood, PF Middleton, A McPhee… - JAMA, 2023 - opus.lib.uts.edu.au
IMPORTANCE: Intravenous magnesium sulfate administered to pregnant individuals before
birth at less than 30 weeks' gestation reduces the risk of death and cerebral palsy in their …
birth at less than 30 weeks' gestation reduces the risk of death and cerebral palsy in their …
Prenatal Intravenous Magnesium at 30-34 Weeks' Gestation and Neurodevelopmental Outcomes in Offspring: The MAGENTA Randomized Clinical Trial.
CA Crowther, P Ashwood… - JAMA: Journal of …, 2023 - search.ebscohost.com
Abstract Key Points: Question: Does intravenous magnesium sulfate for pregnant individuals
at risk of delivery between 30 and 34 weeks' gestation reduce the risk of death or cerebral …
at risk of delivery between 30 and 34 weeks' gestation reduce the risk of death or cerebral …
Prenatal Intravenous Magnesium at 30–34 Weeks' Gestation and Neurodevelopmental Outcomes in Offspring: The MAGENTA Randomized Clinical Trial
CA Crowther, P Ashwood, PF Middleton… - Obstetrical & …, 2024 - journals.lww.com
Preterm birth is a focus of many studies and interventions but remains the leading cause of
global neonatal morbidity and mortality. One particular risk that is elevated in preterm infants …
global neonatal morbidity and mortality. One particular risk that is elevated in preterm infants …
Prenatal Intravenous Magnesium at 30-34 Weeks' Gestation and Neurodevelopmental Outcomes in Offspring: The MAGENTA Randomized Clinical Trial.
CA Crowther, P Ashwood, PF Middleton, A McPhee… - JAMA, 2023 - europepmc.org
Prenatal Intravenous Magnesium at 30-34 Weeks' Gestation and Neurodevelopmental
Outcomes in Offspring: The MAGENTA Randomized Clinical Trial. - Abstract - Europe PMC Sign …
Outcomes in Offspring: The MAGENTA Randomized Clinical Trial. - Abstract - Europe PMC Sign …
Prenatal Intravenous Magnesium at 30-34 Weeks' Gestation and Neurodevelopmental Outcomes in Offspring: The MAGENTA Randomized Clinical Trial.
CA Crowther, P Ashwood, PF Middleton, A McPhee… - 2023 - researchspace.auckland.ac.nz
IMPORTANCE: Intravenous magnesium sulfate administered to pregnant individuals before
birth at less than 30 weeks' gestation reduces the risk of death and cerebral palsy in their …
birth at less than 30 weeks' gestation reduces the risk of death and cerebral palsy in their …
Prenatal Intravenous Magnesium at 30 to 34 Weeks' Gestation and Neurodevelopmental Outcomes in Offspring: The MAGENTA Randomized Clinical Trial
CA Crowther, P Ashwood, PF Middleton… - Obstetric Anesthesia …, 2024 - ingentaconnect.com
(JAMA. 2023; 330 (7): 603–614) Preterm infants have a greater risk of cerebral palsy, a
common motor disability for which there is no cure. As such, primary prevention is especially …
common motor disability for which there is no cure. As such, primary prevention is especially …
Prenatal Intravenous Magnesium at 30-34 Weeks' Gestation and Neurodevelopmental Outcomes in Offspring: The MAGENTA Randomized Clinical Trial
CA Crowther, P Ashwood, PF Middleton… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Importance Intravenous magnesium sulfate administered to pregnant individuals before birth
at less than 30 weeks' gestation reduces the risk of death and cerebral palsy in their …
at less than 30 weeks' gestation reduces the risk of death and cerebral palsy in their …
Prenatal Intravenous Magnesium at 30-34 Weeks' Gestation and Neurodevelopmental Outcomes in Offspring: The MAGENTA Randomized Clinical Trial
CA Crowther, P Ashwood… - JAMA: the journal …, 2023 - research.sahmri.org.au
Importance: Intravenous magnesium sulfate administered to pregnant individuals before
birth at less than 30 weeks' gestation reduces the risk of death and cerebral palsy in their …
birth at less than 30 weeks' gestation reduces the risk of death and cerebral palsy in their …